Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Outcome in patients with isolated regional recurrence after primary radiotherapy for head and neck cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Selecting patients for early clinical trials is a challenging process and clinicians lack sufficient tools to predict overall survival (OS). Circulating cell-free DNA (cfDNA) has recently been shown to be a promising prognostic biomarker. The aim of this study was to investigate whether baseline cfDNA measurement could improve the prognostic information of the Royal Marsden Hospital (RMH) score.

METHODS: Solid tumour patients referred for phase I trials were included in the Copenhagen Personalized Oncology (CoPPO) programme. Baseline characteristics were collected prospectively, including the RMH prognostic score, Eastern Cooperative Oncology Group (ECOG) performance status and concentration of cfDNA per millilitre plasma. Cox proportional hazards model was used to assess the prognostic value of baseline variables.

RESULTS: Plasma cfDNA concentration was quantifiable in 302 patients out of a total of 419 included in the study period of 2 years and 5 months. The RMH score was confirmed to be associated with OS. Cell-free DNA was shown to be an independent prognostic marker of OS and improved the risk model, including RMH, performance status and age. Furthermore, both plasma cfDNA concentration and RMH score were associated with treatment allocation (p < 0.00001).

CONCLUSION: Our model based on RMH score, age, ECOG performance status and cfDNA improved prediction of OS and constitutes a clinically valuable tool when selecting patients for early clinical trials. An interactive version of the prognostic model is published on http://bit.ly/phase1survival .

OriginalsprogEngelsk
TidsskriftBritish Journal of Cancer
Vol/bind121
Udgave nummer2
Sider (fra-til)125-130
Antal sider6
ISSN0007-0920
DOI
StatusUdgivet - jul. 2019

ID: 58968611